← FDA Drug Approvals (Drugs@FDA)
FILSPARI
NDA · New Drug Application · Sponsor: TRAVERE · Approved 2023-02-17
Drug application
- FDA Application #
NDA216403- Application type
- New Drug Application
- Brand name
- FILSPARI
- Generic name
- SPARSENTAN
- Active ingredients
- SPARSENTAN
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- TRAVERE
- Manufacturer
- Travere Therapeutics, Inc.
- First approval
- 2023-02-17
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown